FDA Seeks Comments on Science Board Report
The US Food and Drug Administration is soliciting public comments on the report issued by the Science Board Advisory Committee on December 3, 2007.
The US Food and Drug Administration is soliciting public comments on the report issued by the Science Board Advisory Committee on December 3, 2007.
In its report, the Science Board’s Subcommittee on Science and Technology declared that the FDA is in a “precarious position” and suffers from “serious scientific deficiencies” as a result of soaring demands being placed on the agency while resources have not increased in proportion to those demands.
In its evaluation of the Center for Drug Evaluation and Research (CDER), which focused on pre-market drug assessments, the subcommittee found CDER’s current scientific capabilities to have “glaring and troubling deficiencies.” The report says the Center’s efforts to address these deficiencies is “admirable, but insufficient” and lacks careful planning and the strategic focus necessary to support the rapid advances in science that face CDER staff. It also said the center is typically engaging in a reactive, fire-fighting approach to problem solving, though it marked a more positive note in saying that CDER has “commendable experience and success in transforming itself to respond to new priorities” citing examples of its response to HIV/AIDS and the accelerated drug approval process.
The subcommittee’s evaluation of the Center for Biologics Evaluation and Research (CBER), in contrast, was generally positive. The subcommittee said it was “impressed” with the quality of science, the focused approach to regulatory science, staff stability, and priority setting within the Center. The report did express concerns, however, about lack of funding for the Center and limited ability to provide professional development.
Comments on the report may be submitted until February 4, 2008.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
